8.18
price down icon1.80%   -0.15
after-market Handel nachbörslich: 8.18
loading
Schlusskurs vom Vortag:
$8.33
Offen:
$8.29
24-Stunden-Volumen:
184.99K
Relative Volume:
0.50
Marktkapitalisierung:
$482.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.2168
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+8.63%
1M Leistung:
+3.28%
6M Leistung:
-22.46%
1J Leistung:
-58.92%
1-Tages-Spanne:
Value
$8.07
$8.29
1-Wochen-Bereich:
Value
$7.42
$8.39
52-Wochen-Spanne:
Value
$6.85
$20.74

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name
Firmenname
Cullinan Therapeutics Inc
Name
Telefon
617-410-4650
Name
Adresse
ONE MAIN STREET, CAMBRIDGE
Name
Mitarbeiter
111
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CGEM's Discussions on Twitter

Vergleichen Sie CGEM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CGEM
Cullinan Therapeutics Inc
8.18 491.59M 0 -153.16M -134.48M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-11 Fortgesetzt Stifel Buy
2024-10-24 Eingeleitet UBS Buy
2024-05-01 Eingeleitet Stifel Buy
2024-04-15 Eingeleitet William Blair Outperform
2024-02-15 Eingeleitet Wedbush Outperform
2023-06-15 Eingeleitet TD Cowen Outperform
2022-11-21 Eingeleitet BTIG Research Buy
2021-04-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-02-02 Eingeleitet Evercore ISI Outperform
2021-02-02 Eingeleitet Morgan Stanley Equal-Weight
2021-02-02 Eingeleitet SVB Leerink Outperform
2021-02-01 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten

pulisher
11:34 AM

What is the dividend policy of Cullinan Therapeutics Inc. stockDiscover stocks with explosive upside potential - jammulinksnews.com

11:34 AM
pulisher
10:50 AM

How Efficient Is Cullinan Therapeutics Inc. at Controlling Operating CostsFree Investment Portfolio Suggestions - Newser

10:50 AM
pulisher
10:44 AM

What are analysts’ price targets for Cullinan Therapeutics Inc. in the next 12 monthsMaximize portfolio growth with expert advice - jammulinksnews.com

10:44 AM
pulisher
06:56 AM

Is Cullinan Therapeutics Inc. stock overvalued or undervaluedInvest smarter with daily trading signals - jammulinksnews.com

06:56 AM
pulisher
Jul 26, 2025

How Cullinan Therapeutics Inc. stock performs during market volatilitySafe and Smart Investment Picks - Newser

Jul 26, 2025
pulisher
Jul 25, 2025

What analysts say about Cullinan Therapeutics Inc. stockBreakneck growth rates - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

When is the best time to buy Cullinan Therapeutics Inc. stockFree Stock Chart Pattern Guide - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Cullinan Therapeutics Inc. stock priceSignificant capital appreciation - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 23, 2025

Cullinan Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Cullinan Therapeutics Inc. a good long term investmentUnbelievable profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Breakthrough Lung Cancer Treatment: Zipalertinib Trial Results Reveal New Hope for Hard-to-Treat EGFR Mutations - Stock Titan

Jul 22, 2025
pulisher
Jul 15, 2025

Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Disc Medicine Appoints Nadim Ahmed To Board - citybiz

Jul 14, 2025
pulisher
Jul 14, 2025

Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times

Jul 14, 2025
pulisher
Jul 10, 2025

We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance

Jul 10, 2025
pulisher
Jul 09, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jul 09, 2025
pulisher
Jul 03, 2025

Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia

Jul 03, 2025
pulisher
Jun 30, 2025

Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 21, 2025

Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 21, 2025
pulisher
Jun 20, 2025

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC - insights.citeline.com

Jun 20, 2025
pulisher
Jun 17, 2025

Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World

Jun 17, 2025
pulisher
Jun 12, 2025

Cullinan Management Holds Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech

Jun 12, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus

Jun 11, 2025

Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cullinan Therapeutics Inc-Aktie (CGEM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
AHMED NADIM
President and CEO
Feb 25 '25
Sale
8.53
12,529
106,872
430,621
Michaelson Jennifer
Chief Scientific Officer
Feb 25 '25
Sale
8.53
3,756
32,039
142,004
SUMER JACQUELYN L
Chief Legal Officer
Feb 25 '25
Sale
8.53
3,756
32,039
136,895
Michaelson Jennifer
Chief Scientific Officer
Jan 06 '25
Sale
12.51
4,000
50,040
95,760
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):